Novartis logo - luca dezzani

Novartis drug Votubia® receives EU approval for the treatment of refractory partial-onset seizures in patients with TSC

January 31, 2017 Novartis has announced that the European Commission has approved Votubia® (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalization, are connected with tuberous sclerosis complex (TSC). Votubia is now the first approved pharmacologic therapy in all 28 member states of … Continue reading Novartis drug Votubia® receives EU approval for the treatment of refractory partial-onset seizures in patients with TSC

Advertisements
Best Pharmaceutical Companies at a Glance: Novartis

Best Pharmaceutical Companies at a Glance: Novartis

Novartis is a global healthcare company based in Basel, Switzerland. The company’s portfolio includes innovative pharmaceuticals and oncology medicines, generic and biosimilar medicines and eye care devices. The company operates in three reporting segments including Innovative Medicines (formerly named the Pharmaceuticals Division), Sandoz and Alcon.  About 123,000 people of 144 nationalities work at Novartis globally. … Continue reading Best Pharmaceutical Companies at a Glance: Novartis

Best Selling Oncology Drugs 2016 - Igeahub - Luca Dezzani

Best Selling Oncology Drugs 2016

The top-ten oncology drugs accounted for 36% of the total oncology drugs market. The list is headed by Avastin, an oncology product manufactured by Roche

Igeahub.com - Top Pharma News - Luca Dezzani

Pharma 2016: One Year in Review

Lots of new things happened in the pharmaceutical industry in 2016. At igeahub.com, our mission is to make the pharmaceutical world simple and clear to everyone. We want our readers to have a privileged view on the key player in the healthcare system, and we do our best to keep things simple but highly accurate. The … Continue reading Pharma 2016: One Year in Review

World's 12 Most Reputable Pharmaceutical

The World’s Most Reputable Pharmaceutical Companies 2016

Customers’ satisfaction is immensely important for the pharmaceutical companies. When these companies focus on innovation and act responsibly, they gain the required trust from the customers all over the world. Based on how good people feel about big pharma, a ranking has been published by the Reputation Institute (RI). Based on the ranking, we have … Continue reading The World’s Most Reputable Pharmaceutical Companies 2016

ESMO - Igea - Luca Dezzani

Top News from ESMO 2016

 Immune checkpoint inhibitors for urothelial cancer: New hope with new options 11 Oct 2016 Platinum-based chemotherapy has been the mainstay of treatment for urothelial cancer; however, targeted biologics are now gaining prominence in this setting. Programmed death-1 (PD-1/PD-L1) checkpoint inhibitors facilitate tumour infiltration by T cells, resulting in targeted destruction by the immune system. Advancing … Continue reading Top News from ESMO 2016

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – August 2016

Pfizer Acquires Bamboo Therapeutics and Aims to Become Industry Leader in Gene Therapy August 1, 2016 Pfizer Inc. has announced that it has acquired Bamboo Therapeutics, Inc., a privately held biotechnology company based in Chapel Hill, N.C. Bamboo Therapeutics focused on developing gene therapies for treating patients with certain rare diseases related to neuromuscular conditions … Continue reading Top Pharma News – August 2016

Novartis logo - luca dezzani

Novartis announces positive phase III results showing effectiveness of BAF312 in patients with secondary progressive multiple sclerosis

August 25, 2016 Novartis has announced the results of the Phase III EXPAND study that evaluates the safety and efficacy of oral, once-daily, BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS). The study confirmed that BAF312 met its primary endpoint of a reduction in the risk of disability progression, compared with placebo. This EXPAND study … Continue reading Novartis announces positive phase III results showing effectiveness of BAF312 in patients with secondary progressive multiple sclerosis

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – June 2016

Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic Urothelial Cancer June 6, 2016 Astellas Pharma Inc. and Seattle Genetics, Inc. (NASDAQ: SGEN) have presented first clinical data for ASG-15ME and ASG-22ME at the American Society of Clinical Oncology (ASCO) 51st Annual Meeting that was held in June 3-7, 2016 in Chicago, IL.   … Continue reading Top Pharma News – June 2016

Novartis logo - luca dezzani

Novartis announces long-term safety data of Revolade® in adults with chronic immune thrombocytopenia

June 10, 2016 Novartis has announced data from the largest study of its kind confirming the long-term safety profile of Revolade (eltrombopag) in adults suffering from chronic immune (idiopathic) thrombocytopenia (ITP), with data for up to 6 years in some patients (median exposure was 2.4 years). More data from the study would also show that … Continue reading Novartis announces long-term safety data of Revolade® in adults with chronic immune thrombocytopenia